1,048 results on '"Bartelink, H."'
Search Results
202. Radiotherapy to the conserved breast, chest wall, and regional nodes: Is there a standard?
203. 1. Towards treatment tailoring in breast cancer
204. Evaluation of six process-based forest growth models using eddy-covariance measurements of CO2 and H2 O fluxes at six forest sites in Europe
205. Is reduction of high local recurrence rate in young women possible?
206. Alkyl-lysophospholipids enhance radiation-induced cytotoxicity and inhibit angiogenesis in vitro
207. Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group
208. The relevance of translational research for radiotherapy in breast cancer
209. The value of thallium-201-chloride scintigraphy in staging and monitoring radiotherapy response in low-grade non-Hodgkin's lymphoma
210. Low dose (2 × 2 Gy) involved field radiotherapy in recurrent indolent lymphomas induces rapid and lasting remissions without significant toxicity; results of the HORA-1 phase II study
211. Intensity modulated radiation therapy (IMRT) in breast cancer
212. Commentary on the paper “A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated”. A critical review of an innovative approach
213. Eortc Guidelines for Writing Protocols for Clinical-trials of Radiotherapy
214. Acute toxicity in elderly with head and neck
215. Late toxicity of radiotherapy in elderly patients with head and neck cancer
216. Telemedicine and its impact on cancer management
217. Effects of stand composition and thinning in mixed-species forests: a modeling approach applied to Douglas-fir and beech
218. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer
219. Breast cancer: Post-mastectomy radiotherapy: recommended standards
220. Impact of a boost dose of 16 GY on the local control and cosmesis in patients with early breast cancer: The EORTC ‘boost versus no boost’ trial
221. A Reversal of Fortune - Practical Problems in the Monitoring and Interpretation of An Eortc Breast-cancer Trial
222. Radiotherapy: the last 25 years
223. Selective tumor cell kill by alkyl-lysophospholipids
224. Multimodality approaches in breast cancer: what have we learned?
225. Alkyl-lysophospholipids activate the SAPK/JNK signaling pathway and enhance radiation-induced apoptosis
226. Is neoadjuvant chemotherapy the answer for bladder cancer?
227. Radiosensitivity prediction in head and neck cancer: selection of tumour cells and determination of chromosome aberrations
228. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM)
229. Combined Modality Treatment of Anal Carcinoma
230. Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control
231. The higher local recurrence rate after breast conserving therapy in young patients explained by larger tumour size, incomplete excision at first attempt and smaller excision volume?
232. The influence of the boost on the cosmetic outcome after breast conserving therapy
233. The impact of local control in early breast cancer. Update of the EORTC trials
234. Are risk factors for local and distant recurrence following breast-conserving therapy for early breast cancer similar to those following mastectomy?
235. Postmastectomy radiotherapy: questions for the twenty-first century.
236. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC trial 10801
237. A model of dry matter partitioning in trees
238. Low predictive value of intrinsic fibroblast radiosensitivity for fibrosis development following radiotherapy for breast cancer
239. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin–DNA adduct formation in patients and ovarian cancer cell lines
240. Towards prediction and modulation of treatment response
241. Optimal results in breast conserving therapy: The interaction between the surgeon and radiation oncologist
242. Pathways and time effect of radiation-induced apoptosis
243. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.
244. Quality assurance of the EORTC trial 22881/10882: Boost versus no boost in breast conserving therapy
245. Age is not a limiting factor for radical radiotherapy in pelvic malignancies
246. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial.
247. Post-operative radiotherapy in non-small-cell lung cancer: more questions than answers
248. Feasibility of escalating daily doses of cisplatin in combination with accelerated radiotherapy in non-small cell lung cancer
249. 103 Radiotherapy with concomitant chemotherapy superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the EORTC radiotherapy and gastrointestinal tract cooperative groups
250. SY-3-3 The need for boost doses in breast conserving therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.